Compare Inovio Pharmaceuticals Inc (INO) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Raymond James Financial, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Raymond James Financial, Inc. trades at $169.56 (market cap $32.80B). The key difference: Raymond James Financial, Inc. is far larger — about 367.4× Inovio Pharmaceuticals Inc's market cap, and Raymond James Financial, Inc. pays a 1.28% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | RJF | |
|---|---|---|
Market Cap | $89.27M | $32.80B |
Sector | Health | Financials |
52-Week High | $2.87 | $176.43 |
52-Week Low | $1.05 | $140.89 |
Enterprise Value | $60.28M | — |
Dividend Yield | — | 1.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Raymond James Financial (RJF) trades at $168.23, down slightly by 0.08% on the day. The stock shows a bullish technical trend with moving averages supporting upside momentum, while recent earnings beats and steady revenue growth highlight fundamental strength. Analyst consensus is positive with a $176.83 price target, and the company declared a $0.54 dividend payable in July 2026.
Outlook remains favorable given consistent earnings performance and strong analyst support, though rising expenses and market volatility pose risks. The stock's current valuation metrics, including a P/E of 15.9, suggest room for growth if execution continues. Key catalysts include upcoming Q2 2026 earnings and sustained advisor network expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
